Breakthroughs in the Pathological Mechanism and Comprehensive Management of Pulmonary Hypertension
- 1Department of Respiratory, The Fourth Affiliated Hospital of School of Medicine, and Zhejiang University School of Medicine, International Institutes of Medicine, Zhejiang University, 322000 Yiwu, Zhejiang, China
Abstract
Pulmonary hypertension (PH) is a rare and life-threatening vascular disorder characterized by complex and multifactorial pathogenesis. Emerging evidence indicates that pulmonary vascular remodeling is driven by coordinated abnormalities in genetic susceptibility, epigenetic regulation, metabolic reprogramming, immune-inflammatory crosstalk, and DNA damage repair. Recent advances in multi-omics profiling, single-cell technologies, and high-resolution imaging have substantially improved the understanding of PH pathobiology and disease heterogeneity. Current therapeutic strategies mainly target the three classical vasoactive pathways to alleviate vasoconstriction and improve hemodynamics. Notably, (bone morphogenetic protein) BMP/transforming growth factor‑β1 (TGF-β) pathway-targeted therapy, represented by sotatercept, has initiated a new era of disease-modifying treatment aimed at reversing pulmonary vascular remodeling. In addition, emerging therapies targeting immune, hormonal, and metabolic pathways have demonstrated promising therapeutic potential. Despite significant progress in both basic and clinical research, major challenges remain, including precise phenotypic stratification, long-term therapeutic safety, and individualized treatment optimization. This review summarizes recent advances in the molecular mechanisms and comprehensive management of PH and highlights future directions for translational research and precision medicine.
Related
- Clinical, radiological, and pathological features of pulmonary hypertension associated with combined pulmonary fibrosis and emphysema.
- Pressure-flow discordance in perioperative pulmonary hypertension: a mechanism-based review and provisional five-domain right-heart model for noncardiac surgery
- Resolvin D1 attenuates pulmonary hypertension by suppressing pathological connexin 43-mediated gap junctional communication in pulmonary arterial smooth muscle cells
- The potential core role of the FN1-Hippo signaling axis in the pathological mechanism of autism spectrum disorder
- Effects of podcast supported multicomponent education on treatment adherence and self care management in patients with hypertension
BibTeX
@article{zhou2026breakthroughs,
title = {{Breakthroughs in the Pathological Mechanism and Comprehensive Management of Pulmonary Hypertension}},
author = {Keke Zhou and Yun Gong and Jinxiao Zhang and Doudou Chen and Yu Liu and Zhihao Xu},
journal = {Reviews in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.31083/rcm50716},
url = {https://doi.org/10.31083/rcm50716},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Breakthroughs in the Pathological Mechanism and Comprehensive Management of Pulmonary Hypertension
AU - Keke Zhou
AU - Yun Gong
AU - Jinxiao Zhang
AU - Doudou Chen
AU - Yu Liu
AU - Zhihao Xu
PY - 2026
DA - 2026/10/14
JO - Reviews in Cardiovascular Medicine
DO - 10.31083/rcm50716
UR - https://doi.org/10.31083/rcm50716
AB - Pulmonary hypertension (PH) is a rare and life-threatening vascular disorder characterized by complex and multifactorial pathogenesis. Emerging evidence indicates that pulmonary vascular remodeling is driven by coordinated abnormalities in genetic susceptibility, epigenetic regulation, metabolic reprogramming, immune-inflammatory crosstalk, and DNA damage repair. Recent advances in multi-omics profiling, single-cell technologies, and high-resolution imaging have substantially improved the understanding of PH pathobiology and disease heterogeneity. Current therapeutic strategies mainly target the three classical vasoactive pathways to alleviate vasoconstriction and improve hemodynamics. Notably, (bone morphogenetic protein) BMP/transforming growth factor‑β1 (TGF-β) pathway-targeted therapy, represented by sotatercept, has initiated a new era of disease-modifying treatment aimed at reversing pulmonary vascular remodeling. In addition, emerging therapies targeting immune, hormonal, and metabolic pathways have demonstrated promising therapeutic potential. Despite significant progress in both basic and clinical research, major challenges remain, including precise phenotypic stratification, long-term therapeutic safety, and individualized treatment optimization. This review summarizes recent advances in the molecular mechanisms and comprehensive management of PH and highlights future directions for translational research and precision medicine.
SN - 1530-6550
SN - 2153-8174
ER -